BioSpace News Archive

ProKidney LP, a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease and prevention of end-stage renal disease and need for dialysis, announced the appointment of Todd C. Girolamo as General Counsel.

Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.

Avenge Bio, Inc. today announced the appointment of medical oncologist, Claudio Dansky Ullmann , M.D., as Chief Medical Officer.

NEUVOGEN, an immunoncology company, announced today that Mark Backer , PhD has joined the company as Head of Technical Operations, and will be responsible for leading all aspects of technical operations and chemistry, manufacturing and controls (CMC) technical development for NEUVOGEN’s cancer vaccines.

Revance Therapeutics, Inc. today announced they will give one oral presentation and present one poster at the 2022 American Academy of Neurology Annual Meeting, taking place on April 2-7, 2022 in Seattle, Washington.

Graphite Bio, Inc. announced that Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio, and Matthew Porteus, M.D., Ph.D., one of the company’s academic founders, will be featured speakers on the “CRISPR and Beyond: Advancing Gene Editing Techniques” panel at the H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on Wednesday, March 30, 2022, at 4 p.m. ET.

Husson University will hold its 2022 Commencement Ceremony on Saturday, May 7, 2022 at the Cross Insurance Center in Bangor, starting at 10:30 a.m. During the ceremony, Husson University will pay special tribute to Saundra Pelletier, the chief executive officer (CEO), president, and executive director of Evofem Biosciences (Nasdaq: EVFM ) of San Diego, California.

Ankyra Therapeutics announced today that the Board of Directors has appointed Howard L. Kaufman, MD as Chief Executive Officer effective March 22, 2022.

Click Therapeutics, Inc. today announced the formation of a Scientific Advisory Board (SAB) comprised of an esteemed group of world-renowned healthcare and technology leaders who will help provide scientific guidance to the company as it expands its therapeutic area reach.

Prothena Corporation plc today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody in development for the treatment of Alzheimer’s disease (AD).